GSTM1 and Splenomegaly: Based on these results, we propose that this new dosing strategy may be appropriate for those MF patients commencing ruxolitinib therapy due to splenomegaly and/or MF-associated symptoms who have clinically relevant anemia (Hb < 10 g/dl).